Dramatic response to cyclin D–dependent kinase 4/6 inhibitor in refractory poorly differentiated neuroendocrine carcinoma of the breast. Issue 3 (3rd July 2018)

• Record Type: Journal Article
• Authors: Shanks, Allison; Choi, Julia; Karur, Vinit
• Is Part Of: Proceedings. Volume 31:Issue 3(2018)
• Page Start: 352
• Page End: 354
• Publication Date: 2018-07-03
• Subjects: Cyclin D–dependent kinase 4/6 inhibitor -- neuroendocrine breast carcinoma -- palbociclib; Medicine -- Periodicals; Medicine; Medicine -- Periodicals; Periodicals; Electronic journals; 616.005
• DOI: 10.1080/08998280.2018.1463041
• Languages: English
• ISSNs: 0899-8280

Abstract

ABSTRACT: Neuroendocrine tumors are a rare subset of breast carcinomas. Commonly, platinum-based doublet is used as a systemic treatment option for high-grade neuroendocrine carcinomas from lung, gastrointestinal, and genitourinary origins. In comparison to other breast cancers, neuroendocrine carcinomas have unique genomic features and different treatment strategies. We present a patient with high-grade neuroendocrine carcinoma of the breast who had a successful and durable response to the cyclin D–dependent kinase (CDK) 4/6 inhibitor palbociclib in conjunction with endocrine therapy. This patient was refractory to commonly used platinum-based chemotherapy as well as hormone-based treatment. To date, this is the first published case of use of CDK 4/6 inhibitor in primary neuroendocrine carcinoma of the breast.